Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

NCT07291102 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Medulloblastoma

Interventions

DRUG: Bridging Chemotherapy
DRUG: Induction Cycles A1-A3
DRUG: Induction Cycles A4-5
DRUG: Consolidation Cycle A6
DRUG: HIT-SKK Chemotherapy Cycles B1-3
DRUG: Modified HIT-SKK Cycle B4-5

Sponsor

Nationwide Children's Hospital

Collaborators

[object Object]
[object Object]